Interferon Therapy in Sarcoma and Carcinoma: Mechanisms and Clinical Applications

Interferons (IFNs) are endogenous glycoproteins with antiviral, immunomodulatory, and antitumor properties. While not first-line for most sarcomas or carcinomas, they have established roles in specific subtypes and settings.

Antitumor Mechanisms

1. Antiproliferative: Induce cell-cycle arrest (G1) via p21, p27 upregulation; suppress c-myc, cyclins.
2. Immunomodulatory: Enhance NK cell cytotoxicity, CTL activation, macrophage phagocytosis, MHC class I/II expression, dendritic cell maturation.
3. Antiangiogenic: Downregulate VEGF, bFGF; inhibit endothelial cell migration/tube formation.
4. Pro-apoptotic: Activate intrinsic (caspase-9) and extrinsic (death receptor) pathways; upregulate TRAIL, Fas.
5. Differentiation induction: Promote malignant cell maturation (e.g., in hairy cell leukemia, CML).
6. Synergy with chemo/radiation: Sensitize tumor cells to DNA-damaging agents.

Clinical Indications (Representative)

• Hairy Cell Leukemia: IFN-α2b—high complete response rates; historic standard before cladribine.
• Chronic Myeloid Leukemia (CML): IFN-α—former frontline; now largely replaced by TKIs.
• Melanoma (Adjuvant): High-dose IFN-α2b (ECOG 1684) improves disease-free survival in high-risk resected disease (controversial due to toxicity).
• Renal Cell Carcinoma: IFN-α + bevacizumab (historical); now superseded by VEGF/IO agents.
• Kaposi Sarcoma: IFN-α active in AIDS-related and classic KS.
• Follicular Lymphoma: IFN-α maintenance post-chemo prolongs remission.
• Carcinoid Tumors: IFN-α controls hormone-related symptoms (flushing, diarrhea) and may stabilize disease.

Limitations & Toxicity

• Flu-like syndrome (fever, myalgia, fatigue) — universal, dose-limiting.
• Cytopenias, hepatotoxicity, thyroid dysfunction, neuropsychiatric effects (depression, confusion).
• Autoimmune induction (thyroiditis, SLE-like syndrome).
• Subcutaneous/IM injection 3×/week; pegylated forms allow weekly dosing.

Patient selection is critical. IFNs remain valuable in specific niches (e.g., adjuvant melanoma, KS, carcinoid symptom control) but have been largely displaced by targeted therapies and immunotherapy in most solid tumors.